ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

Addition of Immune Stimulant To Yervoy Therapy Increases Overall Survival, Study Says

November 28, 2014

NS Sponsors Workshop On Prevention For Three Minority Groups

July 1, 1988

Duke Tells ACS The Check for $437,400 Is In The Mail

December 10, 2010

NCI To Recomplete CIDAC Contracts

September 23, 1977

DCPC Advisors Okay New Grant Programs To Improve Participation Of Women, Minorities In Clinical Trials

May 26, 1995

Joe Gray Moves To OHSU Knight Cancer Institute

January 21, 2011